For Physicians Managing Voiding Dysfunction, Improving the Detection Rate of Early Prostate Cancer and Discrimination From Benign Prostatic Hyperplasia, in a Molecular Biomarker Aspects
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Prostate cancer (CaP) is the most common cancer diagnosed among men in the United States and the fifth most common cancer among men in Korea. Unfortunately, the early stages of CaP may have no symptoms. Thus, early detection is very important and physicians managing voiding dysfunction must have awareness about CaP. The traditional tests used for early detection of CaP are the prostate-specific antigen (PSA) blood test and digital rectal examination. However, a high PSA level is not specific for CaP. Benign prostatic hyperplasia, prostatitis, urinary tract infection, and urinary retention can all cause a high PSA level. Thus, no test shows sufficient accuracy to truly be useful for screening men for CaP. A prostate biopsy is the only method that yields a definitive diagnosis of CaP; however, this test is invasive and uncomfortable. Recently, new biomarkers for CaP detection have been proposed to improve the accuracy of the PSA test. In this review, we summarize our knowledge of various new biomarkers, including PSA-associated biomarkers (the prostate health index and 4Kscore), molecular biomarkers (PCA3, TMPRSS2: ERG fusion gene, and various miRNAs), and proteomics-associated biomarkers, and the ways in which they may improve the detection rate of CaP. Accordingly, this review can raise awareness about CaP to physicians managing voiding dysfunction and be a good reference for them.
Abstract
Prostate cancer (CaP) is the most common cancer diagnosed among men in the United States and the fifth most common cancer among men in Korea. Unfortunately, the early stages of CaP may have no symptoms. Thus, early detection is very important and physicians managing voiding dysfunction must have awareness about CaP. The traditional tests used for early detection of CaP are the prostate-specific antigen (PSA) blood test and digital rectal examination. However, a high PSA level is not specific for CaP. Benign prostatic hyperplasia, prostatitis, urinary tract infection, and urinary retention can all cause a high PSA level. Thus, no test shows sufficient accuracy to truly be useful for screening men for CaP. A prostate biopsy is the only method that yields a definitive diagnosis of CaP; however, this test is invasive and uncomfortable. Recently, new biomarkers for CaP detection have been proposed to improve the accuracy of the PSA test. In this review, we summarize our knowledge of various new biomarkers, including PSA-associated biomarkers (the prostate health index and 4Kscore), molecular biomarkers (PCA3, TMPRSS2: ERG fusion gene, and various miRNAs), and proteomics-associated biomarkers, and the ways in which they may improve the detection rate of CaP. Accordingly, this review can raise awareness about CaP to physicians managing voiding dysfunction and be a good reference for them.
참고문헌 (51)
- Siegel RL, "Cancer statistics, 2018", CA Cancer J Clin, 68, pp.7~30 (2018)
- 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2015", Cancer Research and Treatment, 50(2), pp.303~316 (2018), 대한암학회
- 송완, "Incidence of kidney, bladder, and prostate cancers in Korea: An update", Investigative and Clinical Urology, 56(6), pp.422~428 (2015), 대한비뇨의학회
- Obirieze AC, "African-American men with low-risk prostate cancer : modern treatment and outcome trends", J Racial Ethn Health Disparities, 2, pp.295~302 (2015)
- Gann PH, "A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer", JAMA, 273, pp.289~294 (1995)
- Vickers AJ, "A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer : data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden", BMC Med, 6, pp.19~ (2008)
- Stamey TA, "Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate", N Engl J Med, 317, pp.909~916 (1987)
- Filella X, "Emerging biomarkers in the diagnosis of prostate cancer", Pharmgenomics Pers Med, 11, pp.83~94 (2018)
- proPSA and Prostate Health Index(phi)for the detection of prostate cancer : a systematic review and meta-analysis, "Clin Chem Lab Med", 2013, 729~739
- Bruzzese D, "Prostate health index vs percent free prostate-specific antigen for prostate cancer detection in men with"gray"prostatespecific antigen levels at first biopsy : systematic review and metaanalysis", Transl Res, 164, pp.444~451 (2014)
- Russo GI, "A systematic review and meta-analysis of the diagnostic accuracy of prostate health index and 4-kallikrein panel score in predicting overall and high-grade prostate cancer", Clini Genitourin Cancer, 15, pp.429~439.e1 (2017)
- Filella X, "Emerging biomarkers in the detection and prognosis of prostate cancer", Clin Chem Lab Med, 53, pp.963~973 (2015)
- Bussemakers MJ, "DD3 : a new prostate-specific gene, highly overexpressed in prostate cancer", Cancer Res, 59, pp.5975~5979 (1999)
- Filella X, "PCA3 in the detection and management of early prostate cancer", Tumour Biol, 34, pp.1337~1347 (2013)
- Cui Y, "Evaluation of prostate cancer antigen 3 for detecting prostate cancer : a systematic review and meta-analysis", Sci Rep, 6, pp.25776~ (2016)
- Leyten GH, "Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer", Eur Urol, 65, pp.534~542 (2014)
- Berger MF, "The genomic complexity of primary human prostate cancer", Nature, 470, pp.214~220 (2011)
- Esgueva R, "Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort", Mod Pathol, 23, pp.539~546 (2010)
- Mikhaĭlenko DS, "Markers for non-invasive molecular genetic diagnosis of oncourological diseases", Urologiia, (5), pp.116~120 (2014)
- Zhu C, "Expression of miR-30c and miR-29b in prostate cancer and its diagnostic significance", Oncol Lett, 16, pp.3140~3144 (2018)
- Feng S, "Combinations of elevated tissue miRNA-17-92 cluster expression and serum prostate-specific antigen as potential diagnostic biomarkers for prostate cancer", Oncol Lett, 14, pp.6943~6949 (2017)
- Paziewska A, "Candidate diagnostic miRNAs that can detect cancer in prostate biopsy", Prostate, 78, pp.178~185 (2018)
- 윤석중, "Increased Expression of Herpes Virus-Encoded hsv1-miR-H18 and hsv2-miR-H9-5p in Cancer-Containing Prostate Tissue Compared to That in Benign Prostate Hyperplasia Tissue", International Neurourology Journal, 20(2), pp.122~130 (2016), 대한배뇨장애요실금학회
- Al-Kafaji G, "Blood-based microRNAs as diagnostic biomarkers to discriminate localized prostate cancer from benign prostatic hyperplasia and allow cancer-risk stratification", Oncol Lett, 16, pp.1357~1365 (2018)
- Dybos SA, "Increased levels of serum miR-148a-3p are associated with prostate cancer", APMIS, 126, pp.722~731 (2018)
- Porzycki P, "Combination of three miRNA(miR-141, miR-21, and miR-375)as potential diagnostic tool for prostate cancer recognition", Int Urol Nephrol, 50, pp.1619~1626 (2018)
- Tinay I, "Functional roles and potential clinical application of miRNA-345-5p in prostate cancer", Prostate, 78, pp.927~937 (2018)
- Matin F, "A plasma biomarker panel of four microRNAs for the diagnosis of prostate cancer", Sci Rep, 8, pp.6653~ (2018)
- McDonald AC, "Circulating microRNAs in plasma as potential biomarkers for the early detection of prostate cancer", Prostate, 78, pp.411~418 (2018)
- Bryant RJ, "Changes in circulating microRNA levels associated with prostate cancer", Br J Cancer, 106, pp.768~774 (2012)
- Rodríguez M, "Identification of non-invasive miRNAs biomarkers for prostate cancer by deep sequencing analysis of urinary exosomes", Mol Cancer, 16, pp.156~ (2017)
- Korzeniewski N, "Identification of cell-free microRNAs in the urine of patients with prostate cancer", Urol Oncol, 33, pp.16.e17~16.e22 (2015)
- Lewis H, "miR-888 is an expressed prostatic secretions-derived microRNA that promotes prostate cell growth and migration", Cell Cycle, 13, pp.227~239 (2014)
- Srivastava A, "MicroRNA profiling in prostate cancer--the diagnostic potential of urinary miR-205 and miR-214", PLoS One, 8, pp.e76994~ (2013)
- Jentzmik F, "Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours", Eur Urol, 58, pp.12~18 (2010)
- Wu H, "GC", MS-based metabolomic approach to validate the role of urinary sarcosine and target biomarkers for human prostate cancer by microwave-assisted derivatization, 2011, pp.401, 635~646
- Bianchi F, "Fully automated solid-phase microextraction-fast gas chromatography-mass spectrometry method using a new ionic liquid column for high-throughput analysis of sarcosine and N-ethylglycine in human urine and urinary sediments", Anal Chim Acta, 707, pp.197~203 (2011)
- Shamsipur M, "Quantification of candidate prostate cancer metabolite biomarkers in urine using dispersive derivatization liquid-liquid microextraction followed by gas and liquid chromatography-mass spectrometry", J Pharm Biomed Anal, 81-82, pp.65~75 (2013)
- Struck-Lewicka W, "Urine metabolic fingerprinting using LC-MS and GC-MS reveals metabolite changes in prostate cancer : A pilot study", J Pharm Biomed Anal, 111, pp.351~361 (2015)
- Khalid T, "Urinary volatile organic compounds for the detection of prostate cancer", PLoS One, 10, pp.e0143283~ (2015)
- Cai J, "Capillary electrophoresis-mass spectrometry", J Chromatogr A, 703, pp.667~692 (1995)
- Jiang Y, "Quantitative determination of sarcosine and related compounds in urinary samples by liquid chromatography with tandem mass spectrometry", Anal Chem, 82, pp.9022~9027 (2010)
- Heger Z, "Determination of common urine substances as an assay for improving prostate carcinoma diagnostics", Oncol Rep, 31, pp.1846~1854 (2014)
- Tsoi TH, "Urinary polyamines : a pilot study on their roles as prostate cancer detection biomarkers", PLoS One, 11, pp.e0162217~ (2016)
- Sroka WD, "Determination of amino acids in urine of patients with prostate cancer and benign prostate growth", Eur J Cancer Prev, 26, pp.131~134 (2017)
- Fernández-Peralbo MA, "Prostate cancer patients-negative biopsy controls discrimination by untargeted metabolomics analysis of urine by LC-QTOF : upstream information on other omics", Sci Rep, 6, pp.38243~ (2016)
- Gkotsos G, "The role of sarcosine, uracil, and kynurenic acid metabolism in urine for diagnosis and progression monitoring of prostate cancer", Metabolites, 7(1), pp.E9~ (2017)[DOI]
- Dereziński P, "Amino acid profiles of serum and urine in search for prostate cancer biomarkers : a pilot study", Int J Med Sci, 14, pp.1~12 (2017)
- Grönberg H, "Prostate cancer screening in men aged 50-69 years(STHLM3) : a prospective population-based diagnostic study", Lancet Oncol, 16, pp.1667~1676 (2015)
- Van Neste L, "Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk score", Eur Urol, 70, pp.740~748 (2016)
- Van Neste L, "Epigenetic risk score improves prostate cancer risk assessment", Prostate, 77, pp.1259~1264 (2017)